![Resistance to Targeted Therapies in Breast Cancer](/assets/artwork/1x1-42817eea7ade52607a760cbee00d1495.gif)
![Resistance to Targeted Therapies in Breast Cancer](/assets/artwork/1x1-42817eea7ade52607a760cbee00d1495.gif)
![](/assets/artwork/1x1-42817eea7ade52607a760cbee00d1495.gif)
![](/assets/artwork/1x1-42817eea7ade52607a760cbee00d1495.gif)
Resistance to Targeted Therapies in Breast Cancer
-
- €94.99
-
- €94.99
Publisher Description
We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (i.e., EGFR and Wnt signaling). We have also provided an overview of standard of care as an introduction into the importance of targeted therapy. It is our hope that this volume gives an insight into the landscape of breast cancer treatment, the challenges of targeted therapy, and a glimpse into the future of breast cancer therapy.
Other Books in This Series
Resistance of Targeted Therapies Excluding Antibodies for Lymphomas
2018
Resistance to Ibritumomab in Lymphoma
2018
Cancer Stem Cell Resistance to Targeted Therapy
2019
Current Applications for Overcoming Resistance to Targeted Therapies
2019
Resistance to Targeted Therapies in Lymphomas
2019
Resistance to Targeted Therapies in Multiple Myeloma
2021